首页>
外国专利>
USE OF NUCLEOLIN AS A BIOMARKER FOR LYMPHANGIOGENESIS IN A CANCER PROGNOSIS AND THERAPY
USE OF NUCLEOLIN AS A BIOMARKER FOR LYMPHANGIOGENESIS IN A CANCER PROGNOSIS AND THERAPY
展开▼
机译:核蛋白在癌症的预后和治疗中作为淋巴管生成的生物标记物的用途
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors or cancer suppressors, which function in a manner that is analogous to endostatin. The invention is based upon the discovery that nucleolin is specifically expressed on lymphangiogenic vessels and functions as a specific receptor for endostatin, and thus is involved in the signal transduction pathway of endostatin as an anti-lymphangiogenesis inhibitor. The present invention also discloses that cell surface nucleolin on lymphatic endothelial cells is a biomarker for lymphangiogenic vessels, which could be used for the prediction of tumor metastasis.
展开▼